Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 63,400 shares, a growth of 284.2% from the February 29th total of 16,500 shares. Currently, 9.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 21,200 shares, the days-to-cover ratio is currently 3.0 days.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BPTH shares. Roth Mkm lifted their price target on Bio-Path from $12.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday. StockNews.com started coverage on Bio-Path in a research note on Saturday, March 23rd. They set a “sell” rating for the company.

Institutional Trading of Bio-Path

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPTH. Citadel Advisors LLC purchased a new stake in Bio-Path during the 3rd quarter worth about $35,000. Virtu Financial LLC acquired a new position in shares of Bio-Path during the 1st quarter valued at about $38,000. Renaissance Technologies LLC acquired a new position in shares of Bio-Path during the 2nd quarter valued at about $70,000. Walleye Capital LLC purchased a new position in shares of Bio-Path during the 3rd quarter worth about $77,000. Finally, Vanguard Group Inc. boosted its position in shares of Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after acquiring an additional 117,914 shares during the last quarter. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Trading Up 0.5 %

Bio-Path stock opened at $4.04 on Thursday. The stock has a 50-day moving average price of $7.08 and a 200 day moving average price of $8.97. Bio-Path has a 52 week low of $3.51 and a 52 week high of $44.80.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same period in the previous year, the firm posted ($10.60) EPS. As a group, equities research analysts expect that Bio-Path will post -20.8 earnings per share for the current year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.